Articles related to OVARIAN CANCER

ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.

PCOS was associated with significantly elevated risk for breast, uterine, ovarian/fallopian tube, and cervical cancers in a matched cohort of more than 2.5 million women.

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.

Referral rates for newly diagnosed gynecological malignancy occurred in only 14.6% of eligible patients despite attendance rates of 81.7% when referrals were made.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.